Dirk Van Hyfte MD, PhD, Head of Technology,
IPA, to present live demonstration at the InterSystems Global
Summit 2024 June 9-12, 2024 - National Harbor, Maryland
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”)
(NASDAQ: IPA), an artificial intelligence-driven biotherapeutic
research and technology company, today announced that its Belgian
subsidiary, BioStrand, is leveraging their patented Foundation AI
Model, LENSai, by applying advanced Large Language Models (LLM) to
capture real world data from Electronic Health Records (EHR).
LENSai significantly enhances the analysis and integration of EHR
data, enabling the integrated use of real-world data and evidence
in drug discovery and the development of precision medicines.
“IPA’s partners and customers are experiencing impactful results
from the LENSai next generation, HYFT® enabled in silico tools, as
they strive to analyze and utilize increasing volumes of rich
biological data. These valued partners and customers, as well as
potential new users, often encounter challenges with existing omics
processing platforms, which struggle to connect diverse datasets.
Using LENSai, IPA has recently demonstrated the ability to generate
novel in silico antibodies to challenging diseases where
traditional technologies have failed. The ability to efficiently
and effectively utilize EHR further strengthens our value
proposition”, stated Dr. Jennifer Bath, President and CEO of
IPA.
"IPA's BioStrand group continues to innovate. This model has the
potential of dramatically simplifying the connection between
real-world evidence and therapeutic discovery and development."
said Jeff Fried, Director of Platform Strategy & Innovation at
InterSystems. "We're proud that they are using InterSystems IRIS;
with over 40 years’ experience in EHR integration, the InterSystems
IRIS platform is uniquely suited to support BioStrand's
breakthroughs."
Positioning EHR as a High-Value Commodity
As tech giants like Amazon, Microsoft, Apple, and Alphabet
invest heavily in health and wellness, EHRs have become a critical
commodity. By integrating EHRs, BioStrand enhances its ability to
analyze and utilize vast amounts of health data. This capability
enables BioStrand to deliver superior insights and drive innovation
in the rapidly evolving healthcare market.
BioStrand's business opportunity is centered around leveraging
its Foundation AI model to drive innovation in drug discovery and
precision medicine. The integration of this functionality further
strengthens BioStrand's ability to scale its operations and expand
its market reach, positioning the company as a frontrunner in the
biopharmaceutical industry.
"The integration of clinical patient data encapsulated in EHR
systems within our Foundation AI model represents a major step
forward," stated Dirk Van Hyfte MD, PhD, Head of Technology, IPA
(Co-Founder and Head of Innovation, BioStrand). "This
pre-commercial model allows us to leverage extensive patient data,
making more informed decisions and accelerating the development of
personalized therapies."
By invitation, Dr. Dirk Van Hyfte will provide a live
demonstration to industry leaders and developers at the upcoming
InterSystems Global Summit 2024, June 9-12, 2024, in National
Harbor, Maryland. For more details on the event schedule, please
visit the summit's website
(https://www.intersystems.com/global-summit/).
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. has several subsidiaries in North
America and Europe including entities such as Talem Therapeutics
LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and
ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA
Family”). The IPA Family is a biotherapeutic research and
technology group that leverages systems biology, multi-omics
modelling and complex artificial intelligence systems to support
its proprietary technologies in bioplatform-based antibody
discovery. Services include highly specialized, full-continuum
therapeutic biologics discovery, development, and out-licensing to
support its business partners in their quest to discover and
develop novel biologics against the most challenging targets. For
further information, visit www.ipatherapeutics.com.
Forward Looking Information
This news release contains forward-looking statements within the
meaning of applicable United States securities laws and Canadian
securities laws. Forward-looking statements are often identified by
the use of words such as “potential”, “plans”, “expects” or “does
not expect”, “is expected”, “estimates”, “intends”, “anticipates”
or “does not anticipate”, or “believes”, or variations of such
words and phrases or state that certain actions, events or results
“may”, “could”, “would”, “might” or “will” be taken, occur or be
achieved. Forward-looking information contained in this news
release includes, but is not limited to, statements relating to the
expected outcome on the market, the life sciences, drug discovery
and development, integration and / or success of LENSai, LLMs, RAG,
or HYFT technologies, including their benefits, and statements
relating to IPA’s expected increased revenue streams and financial
growth. In respect of the forward-looking information contained
herein, IPA has provided such statements and information in
reliance on certain assumptions that management believed to be
reasonable at the time.
Forward-looking information involves known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements stated herein to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking information. Actual
results could differ materially from those currently anticipated
due to a number of factors and risks, including, without
limitation, the risk that the integration of IPA’s LENSai platform
with its HYFT technology may not have the expected results, risks
that the expected healthcare benefits including lowering
development timeliness, and costs and that development of targeted
treatments with higher efficacy and lower side effects will not be
achieved, risks that the benefits to drug discovery, protein-based
therapeutics, and synthetic biology won't be achieved, in addition
actual results could differ materially from those currently
anticipated due to a number of factors and risks, as discussed in
the Company’s Annual Information Form dated July 10, 2023 (which
may be viewed on the Company’s profile at www.sedar.com), and the
Company’s Form 40-F, dated July 10, 2023 (which may be viewed on
the Company’s profile at www.sec.gov). Should one or more of these
risks or uncertainties materialize, or should assumptions
underlying the forward-looking statements prove incorrect, actual
results, performance, or achievements may vary materially from
those expressed or implied by the forward-looking statements
contained in this news release. Accordingly, readers should not
place undue reliance on forward-looking information contained in
this news release. The forward-looking statements contained in this
news release are made as of the date of this release and,
accordingly, are subject to change after such date. The Company
does not assume any obligation to update or revise any
forward-looking statements, whether written or oral, that may be
made from time to time by us or on our behalf, except as required
by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240604502257/en/
Investor contact: info@ipatherapeutics.com
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Jul 2023 to Jul 2024